Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Eisai Announces Presentations on Perampanel (marketed as FYCOMPA CIII) at the Annual Meeting of the American Epilepsy Society (AES)

Posted on: 23 Nov 17

WOODCLIFF LAKE, N.J., Nov. 22, 2017 /PRNewswire/ -- Eisai Inc. announced today the presentation of eight posters on data, including real-world use of perampanel (marketed as FYCOMPA® CIII). These data will be presented at the American Epilepsy Society (AES) Annual Meeting in Washington, D.C. from December 1-5, 2017.

"Identifying the predictors of response to treatment is invaluable, particularly in managing epilepsy," said Lynn Kramer, M.D., Chief Clinical Officer and Chief Medical Officer, Neurology Business Group, Eisai. "We are pleased to share data on this topic and hope this poster, as well as our other presentations, provide physicians with additional information that may help them expand their knowledge of perampanel and its potential role in treating epilepsy."

For more information:

Editor's Details

Mike Wood

Last updated on: 23/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.